Product details:
| ISBN13: | 9780190920197 |
| ISBN10: | 019092019X |
| Binding: | Paperback |
| No. of pages: | 384 pages |
| Size: | 175x251x22 mm |
| Weight: | 1 g |
| Language: | English |
| 261 |
Category:
Substance Use Disorders
Series:
Primer On;
Publisher: OUP USA
Date of Publication: 9 December 2020
Normal price:
Publisher's listprice:
GBP 59.00
GBP 59.00
Your price:
25 647 (24 426 HUF + 5% VAT )
discount is: 10% (approx 2 850 HUF off)
The discount is only available for 'Alert of Favourite Topics' newsletter recipients.
Click here to subscribe.
Click here to subscribe.
Availability:
Estimated delivery time: In stock at the publisher, but not at Prospero's office. Delivery time approx. 3-5 weeks.
Not in stock at Prospero.
Can't you provide more accurate information?
Not in stock at Prospero.
Short description:
This book addresses the neurobiology, pharmacotherapy, and behavioural therapy of substance use disorders from a clinical perspective. Ideal for residents and fellows, this book will provide a solid background for learning in psychiatry and addiction medicine and can also be used in clinical practice.
Long description:
Substance Use Disorders provides an overview of substance misuse and addresses the neurobiology, pharmacotherapy, and behavioural therapy management of substance use disorders from a clinical perspective. Examining the opioid epidemic to frame its discussion of the epidemiology of substance misuse, this book explores common barriers that prevent the implementation of effective treatment. Chapters discuss various aspects of substance use disorders, particularly opioids, alcohol, cannabis, and cocaine, to inform better conceptualization and management of these conditions. Part of the Primer On Psychiatry series, this book will provide a solid foundation for residents and fellows in psychiatry and addiction medicine and can also be used in clinical practice.
Table of Contents:
Chapter 1: Epidemiology of Substance Use Disorders: Opioid Use Disorder Epidemic
Chapter 2: Epidemiology of Cannabis Use Disorder: Neural Substrates & Treatment
Chapter 3: Preclinical Models of Substance Use Disorder: Abuse Liability Assessment and Candidate Pharmacotherapy Evaluation
Chapter 4: Impulsivity and Drug-Seeking Behavior in Substance Misuse: A Preclinical Perspective
Chapter 5: Impulsivity and Cue Reactivity in Substance Misuse: Clinical Studies
Chapter 6: Stress and Substance Misuse
Chapter 7: Overview: Barriers and Advantages of Utilization of FDA Approved Medications for Substance Use Disorder
Chapter 8: Methadone for Opioid Use Disorder
Chapter 9: Use of Buprenorphine for the Treatment of Opioid Use Disorder
Chapter 10: Antagonist Treatment for Opioid Use Disorder: Development of Antagonist Treatment. Antagonists vs. Agonist Treatments Pros and Cons
Chapter 11: Pharmacotherapy for Opioid Use Disorders in Special Populations
Chapter 12: Pharmacology of Alcohol Use Disorder
Chapter 13: Pharmacotherapy for Smoking Cessation: Overview of Medications Including Over-the-Counter Nicotine Replacement Therapy, Bupropion and Varenicline
Chapter 14: What is "Evidence Based" Treatment?
Chapter 15: Evidence Based Behavioral Therapies for Substance Use Disorder
Chapter 16: Evidence Based Pharmacotherapy for Cocaine, Amphetamine, and Methamphetamine Use Disorder: Overview and History of Clinical Trials
Chapter 17: Evidence Based Pharmacotherapy for Alcohol Use Disorder
Chapter 18: Turn the Next Page: Envisioning the Future of Addiction Therapeutics
Chapter 2: Epidemiology of Cannabis Use Disorder: Neural Substrates & Treatment
Chapter 3: Preclinical Models of Substance Use Disorder: Abuse Liability Assessment and Candidate Pharmacotherapy Evaluation
Chapter 4: Impulsivity and Drug-Seeking Behavior in Substance Misuse: A Preclinical Perspective
Chapter 5: Impulsivity and Cue Reactivity in Substance Misuse: Clinical Studies
Chapter 6: Stress and Substance Misuse
Chapter 7: Overview: Barriers and Advantages of Utilization of FDA Approved Medications for Substance Use Disorder
Chapter 8: Methadone for Opioid Use Disorder
Chapter 9: Use of Buprenorphine for the Treatment of Opioid Use Disorder
Chapter 10: Antagonist Treatment for Opioid Use Disorder: Development of Antagonist Treatment. Antagonists vs. Agonist Treatments Pros and Cons
Chapter 11: Pharmacotherapy for Opioid Use Disorders in Special Populations
Chapter 12: Pharmacology of Alcohol Use Disorder
Chapter 13: Pharmacotherapy for Smoking Cessation: Overview of Medications Including Over-the-Counter Nicotine Replacement Therapy, Bupropion and Varenicline
Chapter 14: What is "Evidence Based" Treatment?
Chapter 15: Evidence Based Behavioral Therapies for Substance Use Disorder
Chapter 16: Evidence Based Pharmacotherapy for Cocaine, Amphetamine, and Methamphetamine Use Disorder: Overview and History of Clinical Trials
Chapter 17: Evidence Based Pharmacotherapy for Alcohol Use Disorder
Chapter 18: Turn the Next Page: Envisioning the Future of Addiction Therapeutics
